Searched over 200M research papers
2 papers analyzed
These studies suggest that metformin can be used safely without significant side effects related to urine production or lactic acidosis risk in certain conditions.
19 papers analyzed
Metformin is a widely used medication for the treatment of type 2 diabetes mellitus. It is a biguanide that helps control blood sugar levels by improving the body's response to insulin. Chemically, metformin is a hydrophilic base that exists predominantly as a cationic species at physiological pH, which limits its passive diffusion through cell membranes.
Metformin is primarily excreted unchanged in the urine. The elimination half-life of metformin in patients with good renal function is approximately 5 hours. The renal clearance (CLR) and apparent total clearance after oral administration (CL/F) of metformin are significantly higher than the clearance of creatinine (CLCR), indicating that metformin is efficiently cleared by the kidneys. Due to this, the dosage of metformin should be adjusted in patients with renal impairment to prevent accumulation and potential toxicity.
Polyuria, or excessive urination, is a known side effect of certain medications, including those used in combination with metformin. In a study involving patients with autosomal dominant polycystic kidney disease (ADPKD) treated with the vasopressin V2 receptor antagonist tolvaptan, it was found that metformin could reduce the polyuria caused by tolvaptan. Specifically, the study showed that metformin decreased the 24-hour urine volume from 6.9 L to 5.4 L, indicating a significant reduction in polyuria.
One of the most serious potential side effects of metformin is lactic acidosis, although its incidence is very low. Lactic acidosis is a condition characterized by the buildup of lactate in the body, leading to a decrease in blood pH. To minimize the risk of developing lactic acidosis, it is recommended that the mean plasma concentrations of metformin be maintained below 2.5 mg/L.
Metformin is an effective medication for managing type 2 diabetes mellitus, with its primary route of excretion being through the urine. While it can cause polyuria, especially when used in combination with other medications like tolvaptan, it also has the potential to reduce polyuria in certain conditions such as ADPKD. The risk of lactic acidosis, although low, necessitates careful monitoring of plasma metformin levels, particularly in patients with renal impairment. Adjusting the dosage in such patients is crucial to prevent adverse effects and ensure safe and effective treatment.
Most relevant research papers on this topic